Pharmacogenomic Testing for CYP2C19 Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory?
The Journal of Applied Laboratory Medicine · 2025
DOI: 10.1093/jalm/jfaf041 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von Alan H B Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University of California, San Francisco, CA, United States. Hauptthemen laut MEDLINE: Clopidogrel, Cytochrome P-450 CYP2C19, Pharmacogenomic Testing, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Clopidogrel is a widely used antiplatelet agent used to prevent adverse events for patients suffering from acute coronary syndromes and ischemic stroke. As a prodrug, clopidogrel must be converted to the active form through the enzyme cytochrome (CYP) P450 2C19 (among other enzymes). Individuals carrying a loss of function (LOF) allele (i.e., *2 and/or *3) have reduced pharmacologic efficacy. Ticagrelor is an alternative antiplatelet medication that is not a prodrug.
Methods
We reviewed the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE2) Trial demonstrating the inferiority of clopidogrel dual therapy with aspirin vs ticagrelor dual therapy to prevent adverse events among patients suffering from a mild stroke among Chinese patients who carried a CYP2C19 LOF. We also summarized the pharmacogenomic testing policies within Chinese clinical laboratories after publication of this trial, and tabulated the CYP2C19 LOF allele frequencies among ancestries, as a criteria for justifying the expense required for establishing pharmacogenomic testing services for other populations.
Results
The CHANCE2 trial showed that stroke patients carrying a CYP2C19 LOF allele(s) had a reduction of 1.6% for recurrent stroke for those treated with ticagrelor vs clopidogrel. The LOF allele frequency was highest among Pacific Island and Western and Central Asian (e.g., Han Chinese) patients and lowest among European, Latin, and Hispanic Latino patients.
Conclusions
Pharmacogenomic testing for CYP2C19 variants is more economically justified for laboratories that serve a population enriched with CYP2C19 LOF alleles, than populations exhibiting a lower allele frequency. Within a clinical laboratory offering testing, restricting testing to certain populations is not ethical.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, University of California, San Francisco, CA, United States.
- Department of Pathology, University of Chicago, Chicago, IL, United States.
- Cipherome, Inc., San Jose, CA, United States.
Zitieren
APA
Wu, A. H. B., Orahoske, C. M., Chen, G., Estabil, J., & Yeo, K. J. (2025). Pharmacogenomic Testing for CYP2C19 Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory?. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf041
Vancouver
Wu AHB, Orahoske CM, Chen G, Estabil J, Yeo KJ. Pharmacogenomic Testing for CYP2C19 Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory?. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfaf041
BibTeX
@article{Wu2025,
author = {Wu, Alan H B and Orahoske, Cody M and Chen, Guanmin and Estabil, Jose and Yeo, Kiang-Teck J},
title = {Pharmacogenomic Testing for CYP2C19 Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory?},
journal = {The Journal of Applied Laboratory Medicine},
year = {2025},
doi = {10.1093/jalm/jfaf041}
}
EUVIMED